eEnzyme, LLC

Marin Biologic blends the fields of cell biology, immunology, molecular biology and biochemistry to tackle complex projects in an innovative and timely manner. We simultaneously utilize our in-depth scientific expertise to collectively approach projects to complement our client’s approach and meet the client’s needs.

Marin Biologic is a woman PhD owned and managed Contract Research Laboratory which specializes in the research, pre-clinical and clinical development and validation of cell based assays and immunoassays for biotech and pharmaceutical companies in Phase I/II or Phase III stages. Our unique approach to collaboration encourages scientists to talk to scientists to create better science.

We are compliant with U.S. FDA cGMP/GLP standards as well as ICH for all levels of clinical development. We employ these standards that are phase appropriate for your clinical development or research.

CEO and President Tania Weiss PhD founded Marin Biologic Laboratories in 1995 to be able to apply her enthusiasm for good scientific process to a broad array of client projects. As a result, the client list as well as the project list is very diverse over the history of the Company. Marin Biologic seeks out and attracts interesting and different scientific opportunities, which puts them at the forefront of scientific development.

Our Lab is located in Novato, California, halfway between San Francisco and the Napa and Sonoma Valleys.

Peter Ralph. PhD, VP Science, peter@marinbio.com
Tania Weiss, PhD, CEO, tania@marinbio.com

415 883-8000
Visit: www.marinbio.com to connect with us, or ask us a question.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

Revolution Biosciences, LLC is a biopharmaceutical discovery company located in the Boston / Cambridge area. Our collaborative R&D discovery model leverages the power of chemical biology to discover and develop transformative medicines in partnership with the life science community. We enable life science companies’ access to cutting edge technologies through consulting agreements, collaborative partnerships and contract research.

We specialize in developing new bioanalytical methods using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) to directly identify proteins, peptides and small molecules and their molecular interactions in all types of biological samples. Our small molecule drug discovery expertise and application of advanced proteomics technologies and biophysical techniques accelerates drug discovery research and our state of the art bioanalytical laboratory is equipped to handle bioanalytical studies from assay development through high throughput screening.

MALDI-TOF is an invaluable tool in Covalent Inhibtion studies. The spectra provide accurate and fast evidence of reversible and irreversible engagement of targeted covalent inhibitors.

Our MALDI product line was initially invented to study the phenotypic responses of cells in culture. The MALDI TOF is capable of providing label-free, fast, accurate analysis of 1000s of individual biomolecules simultaneously and is an ideal method for studying cellular conditions and changes following treatment.

After 25 years in the pharmaceutical world, our founder incorporated Revolution Biosciences at the Venture Development Center at the University of Massachusetts, Boston in March 2015 with the vision of furthering the application of MALDI TOF in life sciencesr esearch.

SHENANDOAH BIOTECHNOLOGY ​- ISO 9001:2015 Certified, Women Business Enterprise Certified

Our scientists have over 60 years combined experience in molecular biology and recombinant protein technology and specializes in folding proteins with biological activity.

Ability to custom engineer and produce almost any recombinant protein your research may require...quickly, economically, and confidentially. Shenandoah is here for your outsourced or contract projects and offers bulk fermentation to generate mg to gram amounts of your target protein.

All recombinant proteins are produced under strict QC/QA protocols and bioassayed to ensure optimal purity, high biological activity and low endotoxin.

Highlights:
10%-50% less expensive than competitors
Unparalleled customer service
Technology transfer packages available
100% satisfaction with products guaranteed

Our recombinant proteins are developed and manufactured in our Pennsylvania facility, USA
New proteins and other products are added quarterly.